Elsevier
Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America
Edition: 1st Edition
Subjects: Medicine,
Hepatology
ISBN13: 9780323323253
Published: 28 Sep 2014
Format -
The release of this order may delay up to 4-6 weeks due to congestion at publisher’s warehouse.
Regular price
A$147.50
Sale price
A$147.50
Regular price
A$152.06
Biologics in Inflammatory Bowel Disease, An issue of Gastroenterology Clinics of North America
Regular price
A$147.50
Sale price
A$147.50
Regular price
A$152.06
Product description
Shipping & Return
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
Shipping cost is based on weight. Just add products to your cart and use the Shipping Calculator to see the shipping price.
We want you to be 100% satisfied with your purchase. Items can be returned or exchanged within 30 days of delivery.